• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Lilly Modifies Purchase Agreement with U.S. for COVID Therapies

    Sanofi Acquires Tidal Therapeutics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Digitalization and the Future of Formulating in Modern R&D Labs

    Sanofi Acquires Tidal Therapeutics
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    Aphena Pharma Solutions

    Reed-Lane

    Almac Group

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    PCI Pharma Services

    Quotient Sciences

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Times, They Are a-Changin’

    For contract organizations and generics, for sure

    The Times, They Are a-Changin’
    Related CONTENT
    • A Potential “Marriage”
    • The Pandemic’s Become an Insurmountable Opportunity
    • Leap, Merck KGaA, Pfizer Partner for Cancer
    • 01 Pfizer, Inc.
    • Elemental Impurity & Risk Assessment
    Emil W. Ciurczak, DoraMaxx Consulting07.20.18
    I have already dedicated several columns to the technical and financial aspects of modernizing client-contract organization relationships. I am always struck by the “Law of Unintended Consequences” (LofUC) and how often it applies to our industry. It can be described as a marriage between a “good news-bad news joke” and Murphy’s Law. For example, in 1983, the EMA (European Medicines Agency) suggested that incoming materials, both active pharmaceutical ingredients (APIs) and excipients, should be qualified for every container, not merely as a combined sample or even √N + 1 (N = number of containers of a particular lot), but all the containers. Clearly, this wasn’t as bad for European companies supplied by rail with large containers. However, in the U.S., we received our materials in many more smaller truck containers. For example, lactose was received in more than 200 bags per batch. Performing USP or EP testing would be prohibitively long and expensive.

    Considering that, in light of the small number of containers in Europe, the Agency didn’t consider that request very burdensome, at least not in Europe. To U.S. companies, it was a huge expense, both in personnel and time spent. Interesting fact: U.S. affiliates of, say, Swiss giants, didn’t make as much income, yet produced more product. The Swiss didn’t have the same anti-trust laws as we did. It was legal, for example for them to “divide up” the continent so as not to have head-to-head competition. Company “A” would sell a sleep aid in Italy and Spain, company “B” would sell a similar product in Germany and France, “C” would have the Benelux countries and Denmark, and so on. In the U.S., direct competition was the norm, so prices had to be competitive, leading to less profit for more product.

    When faced with the massive workload and limited ability to expand personnel and lab space, we turned to what other industries were using, namely food and agriculture. Since USDA (U.S. Dept. of Agriculture) was as regulated as U.S. FDA, I assumed there were reasonable precedents for Near-Infrared Spectroscopy (NIRS) in products consumed by humans.
    Besides the [O=C-N-H] group was essentially the same for Nylon, proteins, and numerous drug substances. The USDA measured water and starch, so did we. And the rest was easy to imagine.

    But, just as Michaelson’s interferometer had to wait for computers to use the centuries-old mathematics of Monsieur Fourier, NIRS—discovered in 1800 and used in agriculture since the 1950s—had to wait for suitable software and hardware. Both occurred in the 1980s and were put to use by the two leading companies of the time: Pacific Scientific (later NIR Systems) and Technicon (later Bran+Leubbe). Qualitative software was developed (H. Mark at Technicon), making the scanning of hundreds of samples in a morning feasible.

    So, commercial NIR was just becoming good enough to be used in the Pharma industry, just when it was most needed. As icing on the cake, secure user passwords and archived data were about to become commonplace, well before 21CFR11 was written. Today, NIR units—both hand-held and riding on carts—are becoming ubiquitous in Pharma warehouses. Speed? Yes, but wait, there’s more. Since NIRS is best used and can only be used for raw materials in a diffuse reflection mode, physical parameters affect the spectra.

    Why is this important for today’s industry? Remember the LofUC? Quite simply, the information that may be gleaned by a few rapid spectral scans used to take days by traditional means: (ang.) particle size, polymorphic form, crystallinity, moisture, and, of course, identity. Since all these parameters are needed for a successful PAT/QbD program, the industry, both initiator and generic, no longer can cry that knowing these BEFORE production is too hard or takes too long. Of course, when one said “rapid” in the late 1980s, they meant rapid versus the hours and days needed to perform “wet” chemistry. A minute or two per sample was lightning fast by comparison. BUT, not fast enough for real-time production.

    One of the barriers to faster, more sensitive instruments was cost. The detectors were either Silicon (Si) for short-range or near-near-IR (400-1100nm) that included the visible range or “normal” NIR of between 1100 and 2500nm, using lead sulfide (PbS) detectors. Interestingly, the NIR range extends to ~3500 or 3600nm, but both the lamps—tungsten-halogen, or wolfram-halogen for the rest of the world—and PbS detectors pretty much stopped measuring at 2500nm. The NIR region was therefore defined, not by theoretical calculation, but by the hardware available at the time.

    A better material was available, namely Indium Gallium Arsenide (InGaAs). It had an extended spectra range and sensitivity and a lower noise component. Sounds great, right? The telecom industry thought so, too. They were, in essence, hoarding whatever supplies could be manufactured for their own uses: long distance and fiber optic communications. The speed and sensitivity made the material excellent for both home and office use as well as long-distance, even trans-continental, lines. The speed of re-emitting signals with extremely low noise made InGaAs perfect for communications and spectroscopy.

    With the industry with far deeper pockets than instrument companies buying every gram they could, the cost to anyone was high. I asked the owner of a NIR instrument company how much a diode array, not even cooled, with InGaAs would cost. He answered, “About $10,000.” So, I asked what they would cost if you bought them in larger lots. His answer: “Still $10,00 apiece.” Then, in the early 1990s there was a telecom deflation, or “crash,” if you prefer, where many companies merged or went out of business. A number of direct consequences arose as a result:
    1. A whole lot of InGaAs for detectors were suddenly available;
    2. The detectors were suddenly far less expensive ($10,000 down to $100); and
    3. A number of suppliers to the industry were without clients.
    Points one and two explain why traditional instruments rapidly became better, but why is point number three important? Well, the choices for the companies who supplied telecom were simple: close down or find a new niche. Some chose the former, packed their tents, and left town. The latter choice was a happy sample of LofUC: these companies took their devices, based on MEMS—”microelectromechanical systems,” or the technology of microscopic devices, particularly those with moving parts, known as micromachines in Japan, or microsystems technology (MST) in Europe—and proceeded in converting them to hand-held spectrometers.

    Yes, they were sometimes “two-hand” held systems and, because of high R&D costs, hardly inexpensive. But, they were battery-powered and portable and the first generation  showing that such devices were possible. These made warehouse inspections much simpler and led to hand-held Raman devices, as well. But, they were not designed for process control. That occurred with a happy coincidence that preceded the PAT (Process Analytical Technologies) Guidance (2002 draft; 2004 final): Pfizer (UK) worked with Zeiss Optics (Switzerland) to develop a rugged NIR instrument that could ride on a bin blender. It had no wires and was battery powered, utilizing fiber optics to “see” into the blender, measuring a scan with every rotation.

    At the time, this 1-3 second scan was sufficient and the time between scans was long enough to allow real-time calculations. This minor break-through allowed for optimization of blending, the first step in enabling PAT as a practical program. Now, we could characterize raw materials and APIs AND follow blending. It was a quick transition to a stationary NIR unit for drying and granulation monitoring, optimizing both steps. The same equipment with fiber optics was then converted to measure coating, in real time in the coating pans. Real-time tablet measurements weren’t there yet, however.

    Another “UC” came out of left field. A company called Spectral Dimensions in Maryland built a wonderfully useful chemical imaging (CI) microscope that showed the components in a sample (e.g., a tablet), where they were, and could quantify each material—excellent for reverse engineering a proprietary formulation, no? It was, sadly, made of expensive components and, in addition to taking several minutes for each sample, it began life at over $150,000. While not adaptable to the process stream, it served to aid in OOS inspections. Eventually, the price escalated to more than $500,000, so production stopped.

    But, seeing the usefulness of CI, VTT, the Technical Research Center of Finland,  developed a dynamic CI device, where the sample or the device needed to move through the length of the sample. This “push-broom” technology was adapted to scanning blister packages, in real time. The latest iteration, produced by Indatech (France), is capable of scanning and evaluating up to 200,000 tablets per hour.

    It’s interesting how seemingly unrelated businesses and technologies have come together to give us affordable PAT/QbD for the masses. In other words, monitoring and controlling solid dosage forms is not just for the “big boys” anymore. Hence the title.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • Manufacturing
    • Dosage
    • Tablet
    • generic
    Suggested For You
    A Potential “Marriage” A Potential “Marriage”
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Leap, Merck KGaA, Pfizer Partner for Cancer Leap, Merck KGaA, Pfizer Partner for Cancer
    01	Pfizer, Inc. 01 Pfizer, Inc.
    Elemental Impurity & Risk Assessment Elemental Impurity & Risk Assessment
    The Final Frontier The Final Frontier
    BioMarin Receives Pfizer Milestone Payments BioMarin Receives Pfizer Milestone Payments
    Schreiner MediPharm Equips Syringes for Pfizer  Schreiner MediPharm Equips Syringes for Pfizer
    Financial Report: Pfizer Financial Report: Pfizer
    We Need to Get Back to Basics We Need to Get Back to Basics
    CPhI NA to Feature Second Women in Leadership Forum CPhI NA to Feature Second Women in Leadership Forum
    Some Changes in Formulation Paradigms Some Changes in Formulation Paradigms
    BioDuro, Pfizer Alliance Creates a Shelf-Stable Reagent BioDuro, Pfizer Alliance Creates a Shelf-Stable Reagent
    Packaging is Neither Simple Nor Un-important Packaging is Neither Simple Nor Un-important
    Getting from Risk Assessment to Regulatory Submission Getting from Risk Assessment to Regulatory Submission

    Related Columns

    • Chemistry | Laboratory Testing
      Back to the Future

      Back to the Future

      All that’s Old is New Again.
      Emil W. Ciurczak, DoraMaxx Consulting 03.01.21

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20


    • Analytical Services | Laboratory Testing
      Re-Open Your Tool Chest

      Re-Open Your Tool Chest

      There’s no longer an excuse NOT to start “PAT-ing” your products
      Emil W. Ciurczak, DoraMaxx Consulting 07.15.19

    • Analytical Services | Laboratory Testing
      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Making a solid case for PAT, QbD and continuous manufacturing in the pharma industry
      Emil W. Ciurczak, DoraMaxx Consulting 03.06.19

    • Analytical Services | Laboratory Testing
      The Great Diaspora of the Pharma Industry

      The Great Diaspora of the Pharma Industry

      Or, good things come in small(er) packages
      Emil W. Ciurczak, DoraMaxx Consulting 11.14.18


    • Analytical Services | Laboratory Testing
      Possibly Time for a New Paradigm

      Possibly Time for a New Paradigm

      Or, why the chicken should cross the road
      Emil W. Ciurczak, DoraMaxx Consulting 10.10.18

    • Analytical Services | Bioanalytical Services | Laboratory Testing
      The Final Frontier

      The Final Frontier

      A look at contract bioprocessing and PAT/QbD
      Emil W. Ciurczak, DoraMaxx Consulting 06.12.18

    • Analytical Services | Laboratory Testing
      We Need to Get Back to Basics

      We Need to Get Back to Basics

      In life, and the lab, the calculator/computer is a blessing and a curse!
      Emil W. Ciurczak, DoraMaxx Consulting 05.08.18


    • Chemistry | Laboratory Testing
      When Your Product is Neither a Liquid or a Solid

      When Your Product is Neither a Liquid or a Solid

      And you need to analyze/control it, in real time.
      Emil W. Ciurczak, DoraMaxx Consulting 01.30.18

    • Analytical Services
      Finding the “Missing Link”

      Finding the “Missing Link”

      Outsourcing and the supply chain
      Emil W. Ciurczak, DoraMaxx Consulting 10.11.17

    • Analytical Services | Laboratory Testing
      Analytical Equipment Technology for the 21st Century

      Analytical Equipment Technology for the 21st Century

      A look at some more toys available for CMOs, CROs and generics to boost their analytical capabilities
      Emil W. Ciurczak, DoraMaxx Consulting 05.09.17


    • Analytical Services
      Quality Risk Management

      Quality Risk Management

      It’s not just for the big guys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 04.03.17

    • Analytical Services | R&D
      Trends in Pharma Analysis

      Trends in Pharma Analysis

      A look at how pharma analysis technology continues to evolve to meet market needs
      Emil W. Ciurczak, DoraMaxx Consulting 03.07.17

    • Analytical Services | Drug Development | Laboratory Testing

      Orphan Drug Development & Production: Turning Lemons into Lemonade

      Forming a “win-win-win” paradigm for large pharma companies, contract service providers and generics
      Emil W. Ciurczak, DoraMaxx Consulting 01.26.17

    Trending
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • ANI Acquires Branded Products Portfolio From Sandoz
    • FDA Accepts Airway Therapeutics’ IND For COVID Treatment
    • Sanofi Invests In Cutting Edge Vax Production Site In Singapore
    Breaking News
    • Lonza Expands PyroTec PRO for Endotoxin Testing
    • FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    • Sanofi Invests in Cutting Edge Vax Production Site in Singapore
    • Lilly Modifies Purchase Agreement with U.S. for COVID Therapies
    • Sanofi Acquires Tidal Therapeutics
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    KD Pharma Acquires Rohner AG Manufacturing Assets
    Thorne Healthtech and PreCon Health to Launch Supplements for Pre-, Post-Impact Brain Health
    Green Leafy Vegetable Intervention Reduces Marker of Colorectal Cancer Risk, Study Finds
    Coatings World

    Latest Breaking News From Coatings World

    BCF's Tom Bowtell Voted VP of World Coatings Council
    Chromaflo Technologies to Sponsor, Exhibit at North American Pultrusion Conference 2021
    EU Innovation Fund Evaluating Perstorp-created Project AIR
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Avantor to Acquire Ritter GmbH and Affiliates for $1B
    ZOLL Buys Sleep Apnea Device Maker Respicardia
    Digital Diabetes Management Market Projected to Reach $54 Billion by 2027
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Lonza Expands PyroTec PRO for Endotoxin Testing
    FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    Sanofi Invests in Cutting Edge Vax Production Site in Singapore
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Honest Co. Files for an Initial Public Offering
    China Builds ‘Beauty and Healthcare Industrial Park’ in Guangzhou
    Edition Spéciale by Luxe Pack is Postponed
    Happi

    Latest Breaking News From Happi

    OTC Pain Relief QR Cream Debuts in US Market
    Professional Beauty Association Opens Registration for Summit
    Makeup Leader Laura Geller Teams Up with Actress Fran Drescher
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Label Traxx launches Siteline online artwork approvals system
    Kocher + Beck appoints new regional sales manager
    Dantex elevates Joseph Sanchez to digital business development manager
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    NXTNano Adding Three Lines
    Honest Company Plans IPO
    Asia Wipes Summit Held Successfully in Shanghai
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    SynerFuse, Cirtec Medical Partner to Develop Back Pain Management Device
    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    NREL: 10 Teams Emerge Victorious in Round 4 of American-Made Solar Prize
    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login